May 11, 2015, 00:00
by
Michael Croft
PRINCETON, NJ - May 11, 2015 - WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for human research and a leading provider of software solutions designed to accelerate clinical trials safely, announced today that its New England Institutional Review Board (IRB) has been reaccredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP)
Reaccreditation underscores
WIRB-Copernicus Group's commitment to conducting high-quality
clinical research reviews
PRINCETON, NJ - May 11, 2015 - WIRB-Copernicus Group (WCG), the
world's largest provider of regulatory and ethical review services
for human research and a leading provider of software solutions
designed to accelerate clinical trials safely, announced today that
its New England Institutional Review Board (IRB) has been
reaccredited by the Association for the Accreditation of Human
Research Protection Programs (AAHRPP). This association serves to
protect the rights and welfare of clinical research participants,
and also to build public trust and confidence in research.
At WCG, we endeavor to attain the highest quality and
efficiency standards in all our business operations and we have our
work reviewed regularly by external experts, commented WCG
Chairman and CEO Donald A. Deieso, Ph.D. As a result, all of our
14 review panels are AAHRPP accredited; our Western IRB and
Copernicus Group IRB are the only two IRBs certified to ISO
9001:2008; and we have also achieved Lean Six Sigma
certification.
New England IRBs AAHRPP reaccreditation underscores WCGs
commitment to championing scientifically and ethically sound
research, safeguarding clinical trial participants, and
demonstrating continuous improvement, said AAHRPP President and
CEO Elyse Summers, J.D.
WCG has always been a strong proponent of the AAHRPP
accreditation process and we consider it to be an important
validation of the high quality of our clinical reviews, said WCG
Chief Compliance Officer David Forster, JD, MA, CIP. In addition
to ensuring that all our IRBs are AAHRPP accredited, we also help
other institutions to achieve that milestone through our WCG
Consulting division.
Founded in 1988, New England IRB is one of the original
independent IRBs established to meet the review needs of sponsors,
contract research organizations, and investigators across the
United States. First accredited by AAHRPP in 2003, New England IRB
was among the first cohort of central IRBs to achieve AAHRPP
accreditation.
AAHRPP accreditation is an intensive process. AAHRPP reviews an
IRBs records, policies, procedures and other materials. It also
performs an on-site inspection of the organizations minutes,
sample protocols and consent forms, and conducts employee
interviews. In addition, AAHRPP requires the IRB to demonstrate an
ongoing commitment to process improvement. AAHRPP accreditation has
to be renewed after three years the first time and then every five
years after that.
Today, New England IRB provides high-quality, full-service,
independent ethical review services to New Englands fast-growing
biopharmaceutical industry, which now accounts for more than 10
percent of the U.S. drug development pipeline.
To learn more about AAHRPP, please visit www.aahrpp.org.
About the WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world's largest provider of
regulatory and ethical solutions for clinical research. The company
provides Institutional Review Board (IRB) and Institutional
Biosafety Committee (IBC) reviews, and Human Research Protection
(HRP), Good Clinical Practice (GCP) and Biosafety consulting
services. Its technology offerings include IRB workflow management
solutions (IRBNet), clinical trial management software for sponsors
and contract research organizations (ePharmaSolutions), and Part-11
compliant online learning solutions for research professionals (WCG
Academy).
The pioneer of independent ethical oversight, WCG continues to
drive progress in the clinical research space. WCG empowers clients
to accelerate life-saving advancements, while ensuring that the
risks of progress never outweigh the value of human life.
For more information, please visit www.wcgclinical.com or follow
us on Twitter @WCGClinical.